Login to Your Account


Lack of regulatory clarity painful for patients, drugmakers

By Mari Serebrov
Washington Editor

Tuesday, April 8, 2014
Lengthening delays in the Drug Enforcement Administration's (DEA) scheduling of new prescription drugs as controlled substances are impeding patient access to much-needed therapies and could be costing lives, a House subcommittee was told during a hearing on legislation intended to improve transparency and predictability at both the DEA and FDA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription